Introduction

History

The path that CorriX has taken
for the healthy and happy daily of human.

2024

  • Participated in Chungbuk Export Trade Mission (Philippines/Indonesia)
  • Participated in Chungbuk Vietnam Consumer Goods Strategic Trade Mission
    (Hanoi/Ho Chi Minh)
  • Participated in Chungbuk Overseas Buyer Invitation Comprehensive Trade Consultation
  • Participated in Bangkok
    International Food Expo, Thailand
  • Participated in Chungbuk Domestic Corporation Making Export Friend Trade Consultation
  • Participated in Chungbuk Agricultural and Food Malaysia Trade Mission
  • Participated in Trade Mission Individual Trip Chungbuk Support Project (Singapore)
  • Participated in Chungbuk B2B Trade Platform Utilization Video Consultation
  • Participated in Overseas Buyers Invitation Chungbuk Agricultural and Food Export Consultation
  • Participated in aT K-FOOD BFK Export Consultation
  • Participated in Chungbuk China (Chongqing, Tianjin, Xiamen)
    K-Consumer Goods Trade Mission
  • Participated in Chungbuk Chongqing Biohealthcare Strategic Mission
  • Participated in Chungbuk SME Purchase Consultation
  • Participated in Chungbuk Asian Strategic Market Total Trade Mission
    (Thailand & Vietnam)
  • Recognized as “Novel Food Ingredient” by the MFDS
  • Participated in export consultation at the World Korean Economic Congress in Austria
  • Participated in individual business trip support project for Singapore
  • Participated in Coex Food Week 2024

2023

  • Applied for Korean trademark
    rights of CorriX
  • Participated in exhibition in Atlanta, USA
  • Participated in Natural Product Expo West 2023 in New Jersey
  • Participated in World Korean Business Congress (WKBC)
  • Participated in SIAL India in India

2022

  • Participated in
    Food Ingredient Europe 2022

2021

  • Signed export contract with Sri Lanka D* Company ($6.4 million / 3 years)
  • Produced CorriX product (scale up)
  • Patent restarted for 'Microorganisms of the species Bacteroides Xylanisolvens' in Germany, Spain, France, UK, and Italy

2020

  • Applied for Chinese trademark
    rights of CorriX

2019

  • Recognized US FDA GRAS Notification
  • European Union EFSA Novel Food
  • Acquired CorriX strain and patent rights from German antibody therapeutics specialist Glycotope GmbH
  • ‘Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates’ patented in Germany, Spain, France, the UK, and Italy
  • Established Immuno-Oncology Research Institute in Sungkyunkwan University School of Medicine

2018

  • ‘Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates’ patented in India
  • ‘Microorganisms carrying a tumor antigen’ patented in Germany, Spain, France, the UK, and Italy

2021

  • CorriX strain introduced in the Nature,
    one of the world’s top three journals
    (Next Generation Probiotics)
  • ‘Fermentation Process’ patented in Germany, France, the UK, Turkey, and the US
  • ‘Microorganisms carrying a tumor antigen’ patented in the US
  • ‘Microorganisms of the species Bacteroides Xylanisolvens’ patented in China Registration

2016

  • Bacteroides Xylanisolvens DSM 23964 Validity Clinical Paper Published in International Academic Journal
  • ‘Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates’ US Patent Registration

2015

  • Applied Europe, UK Trademark of CorriX
  • Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates’ Germany, France, UK, Turkey, China Patent Registration

2014

  • Applied US, India Trademark of CorriX
  • Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates’ Germany, France, UK, Turkey, China Patent Registration

2013

  • Bacteroides ovatus D-6 Validity Non-Clinical Paper Published in International Academic Journal

2012

  • Bacteroides Xylanisolvens DSM 23964 Strain Identification and Safety Preliminary Non-Clinical Paper Published in International Academic Journal
  • Bacteroides Xylanisolvens DSM 23964 Safety Non-clinical Paper International Academic Journal Publication
  • Bacteroides Xylanisolvens DSM 23964 Safety Clinical Paper International Academic Journal Publication